当前位置: X-MOL 学术Cell › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Edaravone: A new drug approved for ALS.
Cell ( IF 64.5 ) Pub Date : 2017-Nov-02 , DOI: 10.1016/j.cell.2017.10.011
Jeffrey D. Rothstein

Amyotrophic lateral sclerosis (ALS) is a progressive, adult onset neurodegenerative disease that is always fatal. The history of ALS drug discovery is fraught with many stops and starts. It took 22 years after the FDA approval of the anti-excitotoxic drug Riluzole before another drug was found to be effective in altering ALS progression: the anti-oxidant Edaravone.

中文翻译:

依达拉奉:一种批准用于ALS的新药。

肌萎缩性侧索硬化症(ALS)是一种进展性,成年发作的神经退行性疾病,总是致命的。ALS药物发现的历史充满了许多停顿和开端。在FDA批准抗激毒性药物Riluzole花费了22年的时间后,才发现另一种可有效改变ALS进展的药物:抗氧化剂依达拉奉。
更新日期:2017-11-02
down
wechat
bug